Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 2.26 CHF -0.44%
Market Cap: 511.1m CHF
Have any thoughts about
Idorsia Ltd?
Write Note

IDIA's latest stock split occurred on Oct 13, 2020

The company executed a 1585-for-1564 stock split, meaning that for every 1564 shares held, investors received 1585 new shares.

Before the split, IDIA traded at 24.8 per share. Afterward, the share price was about 24.12.

The adjusted shares began trading on Oct 13, 2020. This was the only stock split in IDIA's history.

Last Splits:
Oct 13, 2020
1585-for-1564
Pre-Split Price
24.8 24.8
Post-Split Price
24.12
Before
After
Last Splits:
Oct 13, 2020
1585-for-1564

Idorsia Ltd
Stock Splits History

IDIA Stock Splits Timeline
Oct 13, 2020
Oct 13, 2020
Split 1585-for-1564
x1.0134271099744
Pre-Split Price
24.8 24.8
Post-Split Price
24.12
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jul 15, 2025
Brave Bison Group PLC
F:RT7
1-for-20
/20
0.0285 0.57 EUR 0.0001 0.0001 EUR
Jul 15, 2025
Brave Bison Group PLC
LSE:BBSN
1-for-20
/20
3.15 63 GBX 60.5 60.5 GBX
Jul 15, 2025
Mighty Kingdom Ltd
F:9UQ
1-for-5
/5
0.002 0.01 EUR N/A
Jul 14, 2025
Q linea AB
STO:QLINEA
1-for-1000
/1000
0.0591 59.1 SEK 59.4 59.4 SEK
Jul 14, 2025
Passage Bio Inc
NASDAQ:PASG
1-for-20
/20
0.4009 8.018 USD 6.79 6.79 USD
Load More

Idorsia Ltd
Glance View

Market Cap
511.1m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
10.54 CHF
Undervaluation 79%
Intrinsic Value
Price
Back to Top